The pricing of weight-loss and diabetes drugs like Lilly’s Zepbound and Mounjaro, and Novo’s Wegovy and Ozempic, is a pressure point for investors. Price erosion is a major worry amid increasing competition— including from knockoff versions of the drugs provided by telehealth pharmacies and coming patent expirations.

On Thursday, Eli Lilly and Co. (NYSE:LLY) said it will sharply increase the list price of its weight-loss and type 2 diabetes drug Mounjaro (tirzepatide) in the United Kingdom. The moves underscore growing competition with Danish rival Novo Nordisk A/S (NYSE:NVO) in the lucrative obesity drug market.

Using the same discretized logic, let’s consider LLY stock. In the trailing 10 weeks, the market voted to buy LLY six times and sell four times. During this period, the security fell into a downward spiral. Based on the earlier naming logic, we’ll call this a 6-4-D sequence.